Loading
A phase 2 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy is a phase 2, randomised interventional study registered as NCT07101627 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 149 participants, started 2025-08-01 and due to reach its primary completion in 2027-04-30. Interventions recorded: Hetrombopag Tablets. Conditions listed: Lung Cancer. Primary outcome: Incidence of Grade 3 and Higher Thrombocytopenia. Lung eligibility wording from the registry: "Patients with histopathologically confirmed metastatic lung cancer". Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.